Imara Therapeutics
Nov 27, 2019
Novel treatment approval promises a better future for Sickle cell disease patients
Sickle cell disease is a haematological, genetic disorder that affects millions of people worldwide. According to the NIH, “Sickle cell disease is the most common inherited blood disorder in the United States, affecting 70,000 to 80,000 Americans’’. The estimates are somewhat similar to that of CDC’s according t...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
